


A new treatment protocol for advanced head and neck cancer

March 28 2022



MAPK pathway is hyperactive in HNC, and trametinib induced MAPK pathway blockage delays HNC initiation and progression. Credit: *Journal for ImmunoTherapy of Cancer* (2022). DOI: 10.1136/jitc-2021-003917

The current treatment of patients diagnosed with advanced or metastatic head and neck cancer (HNC) is ineffective. Ben-Gurion University of

the Negev researchers, along with their international colleagues, have investigated and validated a potential treatment combination against the aggressive disease driven by hyper-activation of a specific signaling pathway, which is found in over 40% of HNC patients.

Their findings were just published in the *Journal for ImmunoTherapy of Cancer*.

Specifically, the authors showed in pre-clinical HNC models that treating [tumor](#)-bearing mice with a therapy that blocks this [signaling pathway](#), sensitizes tumors to the immunotherapy of anti-PD1, resulting in the disappearance of tumors after the therapy combination. This [effective treatment](#) was validated in four HNC cancer models, and most mice were cured with no recurrent disease. Together with Dr. Pierre Saintygn from Lyon the authors also validated some of the findings in HNC patients.

The research was led by Ph.D. student Manu Prasad in the laboratory of Prof. Moshe Elkabets in the Faculty of Health Sciences at Ben-Gurion University of the Negev.

"Our unique ability to generate pre-clinical HNC models and to investigate new treatment and treatment combinations provides hope for HNC patients. We sincerely hope that oncologists will test this treatment combination in HNC patients, as improving immunotherapy efficacy is crucial for prolonging the survival of cancer patients," says Prof. Elkabets.

The authors also showed for the first time in mice bearing HNC that the treatment should be given sequentially. They found that a short treatment with trametinib is sufficient to sensitize anti-PD-1 resistant tumors. This sensitization happens because trametinib treatment, on the one hand, inhibits tumor cell proliferation and, on the other hand, down-regulates

the expression of an immunosuppressive factor that determines the propagation of immunosuppressive cells in the tumor site. This effect enables cytotoxic white blood cells to reach the tumor site, and together with anti-PD1, can kill the tumor cells efficiently. However, when mice were treated with prolonged trametinib treatment, tumors failed to respond to immunotherapy.

More information: Manu Prasad et al, MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer, *Journal for ImmunoTherapy of Cancer* (2022). [DOI: 10.1136/jitc-2021-003917](https://doi.org/10.1136/jitc-2021-003917)

Provided by Ben-Gurion University of the Negev

Citation: A new treatment protocol for advanced head and neck cancer (2022, March 28) retrieved 22 November 2023 from <https://medicalxpress.com/news/2022-03-treatment-protocol-advanced-neck-cancer.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.